Melperone in the treatment of iatrogenic psychosis in Parkinson's disease

Luca Barbato, Alessandra Monge, Fabrizio Stocchi, Giampietro Nordera

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

The pharmacological management of Parkinson's disease (PD) can be complicated by psychiatric disorders induced by antiparkinsonian drugs. The reduction or withdrawal of levodopa (l-dopa) and other drugs commonly used in the treatment of PD may attenuate the psychosis but exacerbate motor impairment and disability. Melperone is an atypical antipsychotic drug showing in vivo a greater relative affinity for the 5-HT2 than the D2 receptors. A two-year study to assess the clinical efficacy and the safety of melperone in the management of iatrogenic psychosis in 30 parkinsonian patients was carried out. Neurological evaluation was performed with patients in the 'off' and in the 'on' state using the motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). Time spent in 'on' state was evaluated using the self-evaluation diary of daily life. To assess psychiatric disturbances the modified version of the Brief Psychiatric Rating Scale (BPRS) was used. The mean BPRS score was significantly reduced when comparing baseline with individual examinations; no statistically significant differences were found between subsequent examinations. UPDRS motor score and time spent in 'on' state during daily life showed no statistically significant differences when comparing baseline with subsequent examinations. Two patients dropped out because of excessive sedation problems but in the remaining 28 patients melperone proved to be optimally tolerated.

Original languageEnglish
Pages (from-to)201-207
Number of pages7
JournalFunctional Neurology
Volume11
Issue number4
Publication statusPublished - 1996

Fingerprint

Psychotic Disorders
Parkinson Disease
Brief Psychiatric Rating Scale
Psychiatry
Antiparkinson Agents
Diagnostic Self Evaluation
Levodopa
Therapeutics
Pharmaceutical Preparations
Antipsychotic Agents
Pharmacology
Safety
metylperon

Keywords

  • Iatrogenic psychosis
  • Melperone
  • Neuroleptic drugs
  • Parkinson's disease

ASJC Scopus subject areas

  • Clinical Neurology
  • Neuroscience(all)

Cite this

Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. / Barbato, Luca; Monge, Alessandra; Stocchi, Fabrizio; Nordera, Giampietro.

In: Functional Neurology, Vol. 11, No. 4, 1996, p. 201-207.

Research output: Contribution to journalArticle

Barbato, L, Monge, A, Stocchi, F & Nordera, G 1996, 'Melperone in the treatment of iatrogenic psychosis in Parkinson's disease', Functional Neurology, vol. 11, no. 4, pp. 201-207.
Barbato, Luca ; Monge, Alessandra ; Stocchi, Fabrizio ; Nordera, Giampietro. / Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. In: Functional Neurology. 1996 ; Vol. 11, No. 4. pp. 201-207.
@article{5567f8ef5af6408fabb21d3d97575b38,
title = "Melperone in the treatment of iatrogenic psychosis in Parkinson's disease",
abstract = "The pharmacological management of Parkinson's disease (PD) can be complicated by psychiatric disorders induced by antiparkinsonian drugs. The reduction or withdrawal of levodopa (l-dopa) and other drugs commonly used in the treatment of PD may attenuate the psychosis but exacerbate motor impairment and disability. Melperone is an atypical antipsychotic drug showing in vivo a greater relative affinity for the 5-HT2 than the D2 receptors. A two-year study to assess the clinical efficacy and the safety of melperone in the management of iatrogenic psychosis in 30 parkinsonian patients was carried out. Neurological evaluation was performed with patients in the 'off' and in the 'on' state using the motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). Time spent in 'on' state was evaluated using the self-evaluation diary of daily life. To assess psychiatric disturbances the modified version of the Brief Psychiatric Rating Scale (BPRS) was used. The mean BPRS score was significantly reduced when comparing baseline with individual examinations; no statistically significant differences were found between subsequent examinations. UPDRS motor score and time spent in 'on' state during daily life showed no statistically significant differences when comparing baseline with subsequent examinations. Two patients dropped out because of excessive sedation problems but in the remaining 28 patients melperone proved to be optimally tolerated.",
keywords = "Iatrogenic psychosis, Melperone, Neuroleptic drugs, Parkinson's disease",
author = "Luca Barbato and Alessandra Monge and Fabrizio Stocchi and Giampietro Nordera",
year = "1996",
language = "English",
volume = "11",
pages = "201--207",
journal = "Functional Neurology",
issn = "0393-5264",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "4",

}

TY - JOUR

T1 - Melperone in the treatment of iatrogenic psychosis in Parkinson's disease

AU - Barbato, Luca

AU - Monge, Alessandra

AU - Stocchi, Fabrizio

AU - Nordera, Giampietro

PY - 1996

Y1 - 1996

N2 - The pharmacological management of Parkinson's disease (PD) can be complicated by psychiatric disorders induced by antiparkinsonian drugs. The reduction or withdrawal of levodopa (l-dopa) and other drugs commonly used in the treatment of PD may attenuate the psychosis but exacerbate motor impairment and disability. Melperone is an atypical antipsychotic drug showing in vivo a greater relative affinity for the 5-HT2 than the D2 receptors. A two-year study to assess the clinical efficacy and the safety of melperone in the management of iatrogenic psychosis in 30 parkinsonian patients was carried out. Neurological evaluation was performed with patients in the 'off' and in the 'on' state using the motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). Time spent in 'on' state was evaluated using the self-evaluation diary of daily life. To assess psychiatric disturbances the modified version of the Brief Psychiatric Rating Scale (BPRS) was used. The mean BPRS score was significantly reduced when comparing baseline with individual examinations; no statistically significant differences were found between subsequent examinations. UPDRS motor score and time spent in 'on' state during daily life showed no statistically significant differences when comparing baseline with subsequent examinations. Two patients dropped out because of excessive sedation problems but in the remaining 28 patients melperone proved to be optimally tolerated.

AB - The pharmacological management of Parkinson's disease (PD) can be complicated by psychiatric disorders induced by antiparkinsonian drugs. The reduction or withdrawal of levodopa (l-dopa) and other drugs commonly used in the treatment of PD may attenuate the psychosis but exacerbate motor impairment and disability. Melperone is an atypical antipsychotic drug showing in vivo a greater relative affinity for the 5-HT2 than the D2 receptors. A two-year study to assess the clinical efficacy and the safety of melperone in the management of iatrogenic psychosis in 30 parkinsonian patients was carried out. Neurological evaluation was performed with patients in the 'off' and in the 'on' state using the motor examination of the Unified Parkinson's Disease Rating Scale (UPDRS). Time spent in 'on' state was evaluated using the self-evaluation diary of daily life. To assess psychiatric disturbances the modified version of the Brief Psychiatric Rating Scale (BPRS) was used. The mean BPRS score was significantly reduced when comparing baseline with individual examinations; no statistically significant differences were found between subsequent examinations. UPDRS motor score and time spent in 'on' state during daily life showed no statistically significant differences when comparing baseline with subsequent examinations. Two patients dropped out because of excessive sedation problems but in the remaining 28 patients melperone proved to be optimally tolerated.

KW - Iatrogenic psychosis

KW - Melperone

KW - Neuroleptic drugs

KW - Parkinson's disease

UR - http://www.scopus.com/inward/record.url?scp=0029854923&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029854923&partnerID=8YFLogxK

M3 - Article

C2 - 8934152

AN - SCOPUS:0029854923

VL - 11

SP - 201

EP - 207

JO - Functional Neurology

JF - Functional Neurology

SN - 0393-5264

IS - 4

ER -